Bluefield Project

335! We thank #NSP participants & their loved ones, participating @allftd investigators & their teams, sponsors, and the many others who made this achievement possible.

A recent @ScienceMagazine article highlights the creation of the @BluefieldProj and progress over 17 years toward therapies for FTD caused by GRN mutations. 🔗 science.org/content/articl… #FTDResearch #GRN #Progranulin #RareDiseaseResearch #BluefieldProject

𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐃𝐚𝐲 𝐰𝐚𝐬 𝐭𝐡𝐢𝐬 𝐩𝐚𝐬𝐭 𝐰𝐞𝐞𝐤𝐞𝐧𝐝. Our commitment to progranulin-related #FTD research is year-round. Awareness is important. Sustained progress is essential. 💙 #RareDiseaseDay #FTDResearch #CureFTD

Kudos to @Being_Patient_ for this timely coverage of #progranulin (#GRN) FTD and the promising experimental therapeutics being tested in the clinic.

@fenghua_hu Great to see you, and looking forward to your leadership for GC 2028!

@BluefieldProj Look forward to connecting!

@BluefieldProj is attending the Gordon Research Conference for #FTD & Related Rare Dementias (Feb 15–20, 2026). Looking forward to connecting with researchers advancing progranulin & FTD science. Attending? Let’s meet. 📩 info@bluefieldproject.org 👉 tinyurl.com/ycxpjt8b

@BluefieldProj to speak at the #FNIH Biomarkers Consortium Symposium (Feb 9–10, Bethesda, MD). Looking forward to discussions on biomarkers, collaboration, and advancing neurodegenerative disease research—including #FTD. #Biomarkers #FTDResearch #CureFTD #BluefieldProject

Earlier this week, @EliLillyandCo discontinued investigational gene therapy LY3884963 (PR006) for 𝘎𝘙𝘕-FTD, citing lack of efficacy. Data to be shared at a future meeting. Thank you to Lilly, Prevail Therapeutics, and trial participants. #FTDResearch #GRN #CureFTD #CureFTD

Another meaningful way to get involved this year: listening, learning, and staying informed. 🎧 #FTD-focused podcasts and education—like the @RememberMePodcast, @AFTD’s Educational Webinars, and @4theirthoughts' valuable perspectives from families, clinicians, and researchers.

Getting involved doesn’t always start in a lab—it often starts with community. Orgs like @AFTDHope, #CureGRN, @CureMaptFtd , @CurePSP, @End_the_Legacy, #RememberMePodcast and #ForTheirThoughtsFoundation provide vital advocacy, education, and support for families affected by #FTD.

It’s a new year—and a new way to learn about clinical trials. Clinical trials help determine whether new therapies are safe and effective, and participation moves #FTD research forward. 🔬 Explore 𝘎𝘙𝘕 clinical trials: progranulinnavigator.org/directory #FTDResearch #ClinicalTrials #GRN

A new year is a natural time to turn intention into action. Getting involved in FTD research — joining the @EndFTDregistry, studies like #ALLFTD and #GENFI, and exploring clinical trials helps move potential treatments forward. 🔗 progranulinnavigator.org/directory

Attending the #JPM2026 Healthcare Conference next week? If you’re working in #FTDResearch or therapeutic development, the Bluefield Project team would welcome the chance to connect. 📩 info@bluefieldproject.org #JPMHealthcare #Biotech #Neurodegeneration #CureFTD

A new year doesn’t reset the work - it carries it forward. Progress is built over time through collaboration and sustained commitment. Our focus remains unchanged: advancing FTD research, together. Happy New Year! - The Bluefield Team

📚📷 2025 Research Spotlight: Q4 Bluefield-supported Q4 publications advanced #FTDResearch across biomarkers, brain structure, and functional networks—strengthening diagnosis and disease tracking. This post wraps up our 2025 Year-End Research series. 📷💙

❄️ This holiday season, we’re grateful for the researchers, clinicians & collaborators advancing FTD science. Progress happens through collaboration. Wishing you a peaceful holiday season. #FTDResearch #CureFTD #BluefieldProject

📚🔬 2025 Research Spotlight: Q3 Bluefield-supported Q3 publications advanced #FTD research across molecular mechanisms, biomarkers, brain connectivity + global risk factors—from cellular biology to population-level insights. Proud to support this science. 💙 #FTDResearch

📚🔬 𝟐𝟎𝟐𝟓 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭: 𝐐𝟐 Q2: The Bluefield Project-supported publications advanced FTD research across genetics, biomarkers, proteomics, digital health, and disease models—moving the field closer to treatments 💙 #FTDResearch #CureFTD

🔬𝟐𝟎𝟐𝟓 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭: 𝐐𝟏 Highlighting early 2025 publications supported by #TheBluefieldProject—advancing imaging, biomarkers, inflammation research, and cognitive screening in FTD. Proud to support science moving this field forward. 💙 #FTDResearch

📚🔬 Year-End Research Spotlight As 2025 winds down, we’re celebrating the Bluefield-supported studies that advanced imaging, biomarkers, genetics, and disease-mechanism research in FTD. In the coming weeks, we’ll share a quarter-by-quarter look at this year’s key discoveries. 💙

📱 Investigator Spotlight: Remote Monitoring for Decentralized Trials. Drs. Adam Staffaroni (UCSF) & Jonathan Rohrer (UCL) are developing digital tools to make #FTDresearch and trials more accessible, connected+ data-rich. 🔗 boxerlab.ucsf.edu | ftdtalk.org